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INTRODUCTION
Liver transplantation (LT) offers excellent long-term out-
come for certain patients with hepatocellular carcinoma 
(HCC), with a recent push to incorporate markers of 
tumor biology into selection criteria, rather than simply 
focusing on tumor size and number. In this working group 
report, we discuss how selection criteria and acceptable 
posttransplant outcomes for HCC patients undergoing liv-
ing donor LT (LDLT) versus deceased donor LT (DDLT) 
should be different along with the optimal surgical man-
agement of patients presenting with a solitary small HCC. 
The aim of this guideline, approved by the International 
Liver Transplantation Society, is to provide a collection of 
expert opinions, consensus, and best practices surrounding 
LT for HCC. Intended for use by physicians, these recom-
mendations support specific approaches to the appropriate 
use of both deceased donor and live donor LT in the man-
agement of patients with HCC.
DECEASED DONOR LT FOR HCC
Selection Criteria
LT remains the optimal treatment strategy for patients 
with early-stage HCC. LT is thought to be the best onco-
logic resection, replaces the diseased liver, and restores 
normal hepatic function. For patients with HCC exceeding 
the Milan criteria1 (1 lesion ≤5 cm or 2–3 lesions ≤3 cm), 
survival after LT incrementally decreases with increasing 
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tumor size and number2 although modest expansion of 
tumor size criteria to increase access to LT can achieve 
post-LT survival comparable to the Milan criteria.3–10
Especially in areas with organ shortages, the pendulum 
has largely swung away from expanded criteria for sev-
eral reasons. These include an emphasis on performing 
LT in those HCC patients most likely to derive significant 
transplant survival benefit,11 concerns that implementa-
tion of expanded tumor criteria could reduce access to 
LT for patients with better post-LT prognosis,12,13 and 
longer wait times leading to increased use of local-regional 
therapy (LRT) as a bridge to LT.14 There is also mounting 
evidence that tumor burden is just one of many factors 
that predict post-LT outcome.15,16 In this context, selec-
tion criteria have begun to shift to include surrogates of 
tumor biology (eg, alpha-fetoprotein [AFP]) and response 
to LRT, with a number of pre-LT selection criteria recently 
proposed.2,17–22
Recommendations
 1. Indications for LT in HCC are aimed to cure cancer and 
improve patient’s survival and quality of life (quality of evi-
dence: moderate; strength of recommendation: strong).
 2. Selection criteria should consider tumor biology (includ-
ing AFP), tumor size and number, probability of survival, 
transplant benefit, organ availability, waitlist composition, 
and allocation priorities (quality of evidence: low; strength 
of recommendation: strong).
 3. LT is recommended as a first-line option for HCC within 
Milan criteria, unsuitable for low-morbidity resection and 
ablation (quality of evidence: moderate; strength of recom-
mendation: strong).
 4. Consensus on expanded criteria for LT in HCC has not 
been reached but composite criteria that consider surro-
gates of tumor biology and response to neoadjuvant treat-
ments, are likely to replace conventional morphological 
criteria for defining transplant feasibility (quality of evi-
dence: moderate; strength of recommendation: strong).
PREDICTION MODELS FOR DDLT
Most pre-LT prediction models have incorporated 
serum makers in addition to various tumor burden cutoffs 
to more accurately determine recipient benefit. Post-LT 
survival begins to decline at an AFP of ~20 ng/mL23,24 with 
worse survival as AFP increases. Therefore, various cutoffs 
have been utilized for exclusion from LT including >40017 
and >1000 ng/mL in the United States.18 Patients with an 
elevated AFP who have a biochemical response to LRT 
have significantly better post-LT outcome than AFP nonre-
sponders.25,26 Additional serum marker cutoffs associated 
with inferior post-LT outcome include neutrophil-to-lym-
phocyte ratio >5, AFP-L3 >35%, and des-γ carboxypro-
thrombin >7.5 ng/mL19,27,28 though these findings have not 
yet been validated. Several prediction models that allow for 
LT in HCC patients beyond Milan criteria require tumor 
biopsy and exclude patients with poorly differentiated 
tumor grade. With this approach, studies from Padova,29 
Toronto,21 and Hangzhou30 have shown acceptable post-
LT survival in HCC patients beyond Milan criteria. One 
caveat is that the overall agreement of preoperative nee-
dle core biopsy with explant histopathology is relatively 
poor.31,32
Recommendations
 1. Prognostication of post-LT outcome in patients with HCC, 
especially those beyond Milan criteria, should be based on 
measurable pre-LT conditions. Accuracy should be assessed 
in external independent prospective cohorts (quality of evi-
dence: moderate; strength of recommendation: strong).
DOWNSTAGING/BRIDGING TREATMENTS  
FOR DDLT
LRT is frequently used with the aim of controlling 
tumor growth and reducing the risk of waitlist dropout, 
thus serving as a “bridge” to LT. While evidence support-
ing these bridging treatments in reducing waitlist dropout 
is limited, this approach seems justified when the waiting 
time for LT is expected to be at least 6 months.13 Those 
who exhibit tumor progression despite LRT have signifi-
cantly worse post-LT outcomes when compared to those 
who demonstrate treatment response or stable disease fol-
lowing LRT.15,33–35 Observing tumor behavior over time 
after LRT may therefore allow for a more refined selection 
of candidates for LT.36,37
The goal of downstaging is to reduce tumor size so that 
the residual viable tumors fall within acceptable LT criteria 
with most published studies using the Milan criteria as the 
endpoint of downstaging.38,39 The principle behind down-
staging is to serve as a selection tool for a subset of patients 
with HCC beyond conventional LT criteria who would 
respond to downstaging treatments and do well after LT. 
This rationale is supported by the observation that post-LT 
outcomes in those successfully downstaged to Milan criteria 
are not significantly different from those who meet Milan 
criteria at presentation.40,41 There is also correlation between 
successful downstaging and a low prevalence of unfavorable 
explant histologic characteristics.40,42 In the United States, 
in an effort to standardize criteria for downstaging, the 
University of California, San Francisco downstaging pro-
tocol40 has recently been adopted as a national policy for 
granting priority listing for LT. The initial selection crite-
ria are single lesion ≤8 cm, or 2–3 lesions <5 cm with total 
tumor diameter <8 cm, or 4–5 nodules all <3 cm with total 
tumor diameter <8 cm. The application of downstaging also 
involves a minimum observation period of 3 months of dis-
ease stability from successful downstaging to LT.38,40
The use of more liberal inclusion criteria may result in a 
lower rate of successful downstaging and a higher rate of 
waitlist dropout,43,44 as well as inferior post-LT survival.45 
In a recent analysis using the United Network for Organ 
Sharing database,45 Mehta et al observed similar 3-year 
post-LT survival among patients with HCC always within 
Milan criteria (83%) compared to the group successfully 
downstaged using the above inclusion criteria (79%). In 
contrast, the 3-year post-LT survival was significantly lower 
at 71% in the “all-comers” downstaging group with initial 
tumor burden beyond these criteria.
There are obviously safety concerns related to down-
staging, including hepatic decompensation following LRT. 
It has been proposed that only patients with adequate 
hepatic function (Child’s A/B, bilirubin ≤3 mg/dL) should 
undergo downstaging,38 based on recommended guide-
lines for transarterial chemoembolization.46 Transarterial 
chemoembolization is the most commonly used treatment 
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modality in published series38,39 and remains the recom-
mended first-line treatment for downstaging. Y-90 radi-
oembolization has shown promise as a downstaging 
treatment but requires further study.47
Recommendations
 1. Although selection bias is likely, patients with HCC listed 
for LT receiving bridging therapies with objective response 
demonstrate improved waitlist and posttransplant out-
comes (quality of evidence: moderate; strength of recom-
mendation: strong).
 2. Patients beyond Milan criteria can be considered for LT after 
successful downstaging, within defined protocols (quality of 
evidence: moderate; strength of recommendation: strong).
 3. Tumor burden and tumor biology are good predictors of 
successful downstaging of HCC. Eligibility to downstag-
ing should be defined upfront. In case of response, a no-
treatment period to assess end-treatment sustainability is 
recommended (quality of evidence: moderate; strength of 
recommendation: strong).
 4. The degree of tumor response to bridging treatment may 
help in defining LT priority in patients listed with HCC 
(quality of evidence: moderate; strength of recommenda-
tion: strong).
LIVE DONOR LT FOR HCC
Selection Criteria/prediction Models for LDLT
Guided by strong recent evidence, the majority of cent-
ers now use a combination of morphological (eg, Milan,1 
UCSF criteria3) and biological criteria to allocate livers 
for DDLT in patients with HCC, to select those that 
will benefit most from LT. However, in the “no competi-
tion” situation with LDLT, the ethical as well as scientific 
grounds have shifted. Several expanded criteria for LDLT 
have been proposed, although none have been externally 
validated.30,48–54 The question that still remains is how 
far LT criteria can be expanded without adversely affect-
ing the double equipoise in LDLT, namely ensuring both 
acceptable recipient outcomes and donor safety.55
Some predictive models incorporating tumor biology 
in selection criteria combining tumor burden, biomarkers, 
and18F-FDG PET avidity have been reported in the LDLT 
setting, including the National Cancer Center Korea and 
Japanese criteria.28,56–60 One interesting aspect regarding 
selection criteria is that centers with longer wait times use 
downstaging/response to LRT by necessity whereas centers 
which primarily perform LDLT and have short wait times 
tend to have fairly liberal tumor burden criteria but rely 
heavily on biomarkers and/or negative18F-fluorodeoxyglu-
cose positron emission tomography scan. FDG-negative 
patients beyond Milan criteria have satisfactory post-LT 
outcome56,58–60 whereas those with a tumor to nontumor 
ratio >2 tend to do poorly. In the future, molecular crite-
ria (eg, angiotensin 2, VEGF, miR-718, pERK, glycipan 3, 
osteopontin) may take center stage.61,62
Recommendations
 1. Selection criteria for patients with HCC may be different 
in LDLT than DDLT in selected cases (quality of evidence: 
moderate; strength of recommendation: strong).
 2. Selection of patients outside standard criteria for LDLT 
may use validated criteria based on AFP and DCP cutoffs 
(eg, <400 and <7.5 ng/mL, respectively),18F-FDG PET non-
avid tumor, and if applicable, response to LRT to ensure 
acceptable tumor biology. They should have no extra 
hepatic disease and/or macrovascular invasion (quality of 
evidence: moderate; strength of recommendation: strong).
Defining Minimal Survival Benefit Combined With 
Donor Risk
Attempting to maximize recipient benefit while mini-
mizing donor risk reflects the basic tenet of achieving 
double equipoise.55,63,64 There are perceived risks of trans-
planting patients with HCC too quickly without a minimal 
period of observation for tumor progression, as illustrated 
in the “fast-tracking” and “ablate and wait” concepts.36,65 
Additionally, there has been concern that graft regenera-
tion in LDLT could lead to tumor growth and recurrence. 
However, several series and a meta-analysis have shown 
that LDLT achieves comparable outcomes to DDLT in 
HCC, thus largely negating these concerns.66,67
Previous reports have proposed an acceptable mini-
mum survival of 50% at 5-year after LDLT for HCC.68 
An International HCC Consensus Conference report from 
201213 suggested that expansion beyond Milan criteria 
should take into account the effect of delaying LT for 
all potential waitlist candidates, including the ones with 
nontumor indications. Hence, the resulting proposal was 
to reserve LDLT for HCC patients who have an expected 
survival comparable to that of non-HCC patients (ie, 
70%–80% at 5 y). Using a Markov model, Volk et al12 
showed that the adverse effects of expanding LT criteria 
would outweigh its benefits if the expected 5-year overall 
survival of a patient transplanted outside Milan criteria 
was <61%. Taking each of these previous reports into 
consideration, we believe that a minimum 5-year post-
LDLT survival of 60% is an acceptable benchmark.
The triple (triangular) equipoise concept elaborates 
on the balance of 3 ethical dimensions—donor safety, 
expected recipient outcome, and recipient need.69 The risk 
of death for a recipient with a LDLT option is approxi-
mately half that of a patient awaiting DDLT without live 
donor options70 and this risk falls even further if an HCC 
patient with an LDLT option has a MELD score >15.71 
Hence, it seems clear that HCC patients benefit from and 
deserve LDLT, especially in areas where DDLT rates are 
low.72 Similar to the paradigm with DDLT, the “transplant 
benefit” principle73 is a key concept for LDLT. By prioritiz-
ing patients based on life-years gained with LT, the trans-
plant benefit principle performs better than urgency and 
utility schemes from a population perspective.74
In terms of donor risk, a worldwide survey with 11 553 
liver donors reported a mortality of 0.2%, transplant rate 
of 0.04% for donor liver failure, and an overall donor 
morbidity of 24%.75 An overall donor complication rate 
of <27% with <6% Clavien-Dindo grade 3/4 complica-
tions has been considered acceptable in a benchmark 
study.76 However, we believe that centers should aim for 
zero donor mortality with maximum acceptable live donor 
risk of <20% for Clavien grade I/2 complications and <5% 
for grade 3/4 complications.77
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Recommendation
 1. Minimum acceptable recipient overall survival should be 
60% at 5 years after LDLT (quality of evidence: moderate; 
strength of recommendation: strong).
 2. The goal live donor risk should be a Clavien 1/2 complica-
tion rate <20% and 3/4 rate <5% aiming for zero donor 
mortality (quality of evidence: moderate; strength of rec-
ommendation: strong).
 3. The donor should be informed about the recipient’s prog-
nosis based on established criteria, center results, and 
published evidence (quality of evidence: low; strength of 
recommendation: strong).
Role of Tumor Downstaging in LDLT
Whereas the “ablate and wait” policy is relevant 
in DDLT, its applicability for LDLT is questionable. 
Downstaging tumors from beyond to within conventional 
criteria has been demonstrated to improve outcomes in 
HCC patients following LT39–42 though most downstag-
ing studies have been primarily in the DDLT setting. Only 
approximately 60% of patients with HCC beyond conven-
tional downstaging criteria (so-called “all-comers”) can 
be successfully downstaged to Milan criteria with LRT.43 
Therefore, UCSF criteria may be a more achievable down-
staging endpoint before LDLT. Although some case series 
have reported successful downstaging of HCC with portal 
vein tumor thrombus often using Y-90 radio-emboliza-
tion,78–81 the small number of patients and limited follow 
up make it difficult to propose guidelines for LDLT in this 
population at present.
Recommendations
 1. HCC patients with tumor size and number beyond their 
“local” criteria should be downstaged with LRT at least to 
within UCSF criteria with AFP <500 ng/mL before LDLT. 
An observation period of at least 3 months after success-
ful downstaging is suggested before LDLT (quality of evi-
dence: moderate; strength of recommendation: strong).
MANAGEMENT OF SINGLE, SMALL HCC
Liver Transplantation Versus Hepatic Resection
Hepatectomy for early-stage HCC is increasingly being 
performed due to both increased HCC incidence and 
organ shortages, and offers 5-year survival rates up to 
60%.82 There are no randomized control trials evaluating 
resection versus LT, leading to the ongoing debate of which 
is most appropriate for patients within Milan criteria and 
adequate liver function. Resection confers up to 10-fold 
higher odds of recurrence compared to LT1,83,84 and 
underlying cirrhosis increases recurrence risk after resec-
tion compared to normal background liver.85 In patients 
without significant fibrosis, resection is universally advised 
as first-line treatment, but in patients with compensated 
cirrhosis, recommendations are mixed and vary by tumor 
size and number.86
In patients otherwise eligible for LT, postresection 
5-year recurrence-free survival is 40%–50%.87,88 While 
10-year overall survival is better with LT for resectable 
HCC,89 many studies have shown similar 5-year overall 
survival for resection compared to LT in patients with a 
single <3 cm HCC.89,90 Patients with a single <3 cm HCC 
have improved outcome compared to those with larger 
tumor burden regardless of resection versus LT.91–93 More 
recently, a large multinational study94 reported a ~40% 
cure rate with resection (compared to 75% with LT) in 
patients with single <3 cm HCC and MELD <11 with sim-
ilar intention-to-treat survival given the expected 10%–
20% waitlist dropout rate in those awaiting LT.
The question of offering LT to resectable, Child’s A 
patients with single small HCC takes on greater impor-
tance after Berry and Ioannou95 found that HCC patients 
derive a significantly lower survival benefit from LT than 
non-HCC patients. Further, several studies have shown 
that HCC patients with favorable tumor (single tumor 
<3 cm and AFP ≤20 ng/mL) and liver-related characteris-
tics (Child’s A cirrhosis and MELD-Na <15)11,96,97 have 
reduced urgency for LT. Such patients who subsequently 
undergo LRT with complete radiographic response have 
a very low risk of waitlist dropout11,96,98 and thus exceed-
ingly low LT urgency with decreased LT survival benefit.37 
This is especially true for HCC patients unlikely to have 
liver disease progression (eg, due to effective antiviral 
treatment or alcohol abstinence) and thus no alternate 
indication for LT.
Recommendations
 1. HCC patients with compensated liver disease and minimal 
tumor burden have a low risk of waitlist dropout and do 
not derive the same immediate benefit from LT as other 
waitlist candidates (quality of evidence: moderate; strength 
of recommendation: strong).
 2. Particularly in areas of organ shortages, due to competi-
tion with patients with higher transplant benefit, deceased 
donor LT is recommended only as second line treatment in 
resectable patients with single <3 cm HCC in case of tumor 
recurrence or liver failure after resection or ablation (qual-
ity of evidence: moderate; strength of recommendation: 
conditional).
 3. Patients with well-compensated disease and single <3 cm 
HCC with complete response to LRT have reduced the 
urgency for LT (quality of evidence: moderate; strength of 
recommendation: strong).
Salvage Liver Transplantation
For patients undergoing resection, the strategy of sal-
vage LT (SLT), or performing LT after recurrence within 
conventional transplant criteria, appears effective in 50%–
60%99,100 with intention-to-treat survival >80% at up to 
10 years in patients who either do not recur after resec-
tion or who undergo LT after recurrence.99 Importantly, 
having early-stage HCC at resection predicts success with 
the SLT strategy.99 Similarly, Lee et al101 found that initial 
disease within Milan, single tumor, and lack of lymphovas-
cular invasion predicted decreased likelihood of postresec-
tion recurrence beyond Milan criteria. Patients with single 
<3 cm HCC would be expected to only have a 10-30% 
chance of recurrence beyond Milan and would likely be 
candidates for SLT in case of recurrence. Additionally, 
a recent systematic review and meta-analysis102 found 
improved 5-year post-LT survival after SLT compared 
to primary LT and concluded that SLT may be a better 
treatment strategy for recurrent HCC in compensated 
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patients initially eligible for resection. While unlikely to 
apply to most patients with a single, small HCC, proposals 
to perform LT after resection in patients with a high risk 
for recurrence (eg, microvascular invasion and/or previ-
ously undiagnosed satellite lesions)103,104 require further 
validation.
Recommendations
 1. Patients with single <3 cm HCC who undergo resection but 
have tumor recurrence are highly likely to be eligible for 
SLT (quality of evidence: moderate; strength of recommen-
dation: strong).
 2. SLT and primary LT appear to have equivalent outcomes 
from the time of LT (quality of evidence: moderate; strength 
of recommendation: strong).
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